Anti-migraine drugs, including triptans, are not indicated for use in pregnancy. However, the
peak prevalence of migraine is in women of childbearing age. This, coupled with the sporadic
nature of migraine attacks and high rates of unplanned pregnancies, makes unintentional
exposure to anti-migraine medications during pregnancy likely. Prior to an anti-migraine
medication being marketed there are few data available on drug safety in pregnancy: data from
animal models may not translate directly to humans and pregnant women are routinely excluded
from clinical trials. The Sumatriptan Pregnancy Registry was established by GlaxoSmithKline
(GSK) in 1996 to monitor the safety of sumatriptan during pregnancy. It was combined with the
Naratriptan Pregnancy Registry in 2001 and data collection on the sumatriptan-naproxen
combination (Treximet) began in 2008.